A method of identifying or evaluating skin-care actives that improve the metabolism of a skin cell. The method includes contacting cells with a stressor and a test agent and determining a response of the cells to the stressor and test agent, based on the change in metabolic indicators associated with glycolysis and/or oxidative phosphylation. The test agent may be identified as a skin-care active when the oxidative phosphorylation and/or glycolysis response corresponds to an improvement in cellular metabolism.

A composition containing a material for regulating the expression of ABH antigens and, more specifically, to a composition capable of: controlling sebum production and alleviating skin trouble by regulating the expression of ABH antigens; preventing skin pore enlargement by providing antioxidant effects; and defending against skin irritation production and method of using the composition are disclosed.

The present disclosure is directed a method for evaluating a sunscreen. The method comprises measuring a protective effect of a sunscreen and at least one cellular alteration caused by irradiation. The measured effects are evaluated against a control for the at least one cellular alteration caused by irradiation.

The present disclosure relates generally to methods and apparatus for profiling the components and associated conditions in a dermatological sample, and preparing personalized cosmetics or treatments. In particular, the present disclosure relates to the use of surface desorption ionization-mass spectrometry apparatus and omics methodologies to profile or fingerprint dermatological samples, such as skin and hair samples, for personalized cosmetics. In particular, the method and apparatus can allow real time mass spectrometry-based lipidomics and metabolomics to phenotype skin and hair samples for molecular personalized cosmetics.

Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.

Various aspects of the invention relate to compositions and methods for preventing and treating skin conditions, such as acne. Also provided herein are methods of determining whether a subject is at risk for a skin condition.

The present invention relates to: biomarker proteins for diagnosing scars; a composition for diagnosing scars by using the same; a biochip for diagnosing scars; and a method for obtaining information on the scars. Proteins identified by the present invention can be applied as biomarkers for screening scars. A patient with keloid scars can be diagnosed by using the biomarker. In addition, the biomarker can be used for treating a patient with keloid scars.

In various embodiments, provided are methods for selecting and formulating compositions for treating and maintaining the quality of skin in a select population, wherein a composition is selected for use in a personal care product based on its demonstrated biological effect to improve skin quality in the population as evidenced by one or more biomarker changes that correlate with improvement as evidenced by one or more objective measurements of skin health in the population.

A kit is constituted by: a stratum corneum collecting device formed by a rod shaped portion having a grip portion to be gripped by a user at one end, a columnar portion which is continuous with the other end of the rod shaped portion, and an adhesive layer formed on a circumferential surface of the columnar portion; and a solvent container, a solvent container, which is a bottomed cylindrical container having an opening in an upper portion thereof, containing a solvent for extracting a component from stratum corneum collected by the adhesive layer, the solvent container receiving the columnar portion of the stratum corneum device through the opening so as to enable the adhesive layer to be immersed in the solvent. A lid and a solvent outlet, which is opened to take the solvent out from the interior of the solvent container, are provided.

The present disclosure provides diagnostic methods, that may be combined with medical treatment, using one or more plasma biomarkers that are useful for identifying a subject with Hidradenitis Suppurativa (HS), measuring disease severity of HS, and measuring clinical response in subjects with HS.